click below
click below
Normal Size Small Size show me how
intro to pharm 2
exam 1
| Question | Answer |
|---|---|
| zero order rate processes | the rate of drug elimination is independent of drug concentration |
| first order rate processes | the rate of drug elimination is dependent of drug concentration |
| what rate process are majority of drugs? | first order |
| pathways of renal clearance | glomerular filtration, tubular secretion, reabsorption |
| what does glomerular filtration affect? | all solutes of appropriate sizes |
| MW of glomerular filtration | </= 500 D |
| what is glomerular filtration influenced by? | protein binding |
| glomerular filtration is? | passive and unidirectional |
| tubular secretion occurs mostly in the? | proximal tubules of the nephron |
| tubular secretion requires? | a carrier protein to bring drugs out |
| what kind of process is tubular secretion? | saturable |
| is tubular secretion influenced by protein binding? | no |
| where does reabsorption occur? | all along the nephron |
| reabsorption is passive by? | nature and active |
| reabsorption favors? | lipid soluble, unionized drugs |
| in reabsorption, weak acids and weak bases depend on? | the urine pH and the pKa of the drug |
| renal clearance | a net result of filtration, secretion, and reabsorption |
| effect of secretion on renal clearance | higher renal clearance |
| effect of reabsorption on renal clearance | lower renal clearance |
| dosing in pediatrics | weight-based dosing |
| dosing in geriatrics | dosing modifications based on a reduction in clearance secondary to reduction in liver and kidney function |
| what do oxidation, reduction, and hydrolysis reactions introduce? | functional groups to increase a drug's water solubility and can dramatically alter its pharmacological activity |
| concepts of pharmacodynamics | drug in tissues, pharmacologic or clinical effect |
| sigmoid curve | there is a relationship between drug concentration and effect |
| EC50 | 50% effective concentration |
| drug tolerance | 50% mark is the same but concentration to reach is higher |
| what type of therapeutic window do we ideally want? | wide, where there is little to no overlap between therapeutic doses and toxic doses |
| what type of therapeutic windows do most drugs have? | narrow therapeutic windows |
| with narrow therapeutic drugs, small changes in dose result in? | large increases in the likelihood of toxicities |
| types of drug-receptor interactions | agonists, antagonists, allosteric interactions |
| agonists | full agonists, partial agonists, inverse agonists |
| full agonists | cause downstream effects |
| partial agonists | partial downstream effects |
| inverse agonists | opposite of what its supposed to be |
| antagonists | competitive antagonists, non-competitive antagonists |
| competitive antagonists | one binding site drug competes with to bind on receptor |
| non-competitive antagonists | multiple binding sites |
| allosteric interactions | allosteric activators, allosteric inhibitors |
| therapeutic index | the range of doses at which a medication is effective without unwanted adverse events/toxicities |